| P/E (FY) | — | Sales (TTM) | $3.8M |
| Earnings (TTM) | -$7.3M | ROE | −397.80% |
| Net Margin | −238.31% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 1.79% |
| Market Cap | $38.6M | Trading Days | 4652 |
| 52W High | 1.60 |
| 52W Low | 0.66 |
| % Off High | −33.75% |
| YTD | 12.77% | 1Y | −4.50% |
| 3Y | −40.45% | 5Y | −68.82% |
| 10Y | −33.75% | Since incept. (ann.) | 1.53% |
Grant 60% · Research And Development 31% · License 9%
| Ann. Volatility (1Y) | 81.55% | Ann. Volatility (3Y) | 74.21% |
| Sharpe (1Y) | 0.34 | Sharpe (3Y) | 0.12 |
| Max Drawdown (1Y) | −47.79% | Max Drawdown (3Y) | −70.10% |
| Beta (3Y, vs SPY) | 0.98 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| EXOZ | EXOZYMES INC. | $37.3M | — |
| ELUT | ELUTIA INC. | $42.0M | 1.1 |
| INMB | Inmune Bio, Inc. | $45.5M | — |
| MGX | Metagenomi Therapeutics, Inc. | $45.6M | — |
| ESLA | Estrella Immunopharma, Inc. | $32.2M | — |
| ATYR | aTYR PHARMA INC | $48.4M | — |
| TIL | Instil Bio, Inc. | $49.4M | — |
| INKT | MiNK Therapeutics, Inc. | $52.5M | — |
| CRDF | Cardiff Oncology, Inc. | $55.9M | — |
| SCLX | Scilex Holding Co | $57.9M | — |
| GRML | Greenland Mines Ltd | $24.1M | — |
| TVGN |
| Tevogen Bio Holdings Inc. |
| $23.4M |
| — |
